Biomarker-Driven and Molecular Targeted Therapies for Colorectal Cancers

Publication date: Available online 4 July 2017
Source:Seminars in Oncology
Author(s): Marta Schirripa, Stacey A. Cohen, Francesca Battaglin, Heinz-Josef Lenz
The improved clinical selection and the identification of new molecules and innovative strategies widened treatment options and increased overall survival in metastatic colorectal cancer patients in recent years. Biomarker-driven therapies represent an emerging issue in this field and new targeted treatments are under investigation and will be probably soon adopted in the daily clinical practice. In the present review the role RAS, BRAF mutations, Her2 amplification, microsatellite instability and CpG Island Methylator Phenotype are reviewed and discussed according to their possible role as prognostic, predictive markers as well as possible biomarker-driven treatment options.



http://ift.tt/2sEs9nA